ClinicalTrials.gg
TerminatedNCT02609048Updated Feb 25, 2025Results posted

Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)

A Phase 2 interventional study of Placebo Comparator and Experimental: Seladelpar 50 mg in Primary Biliary Cirrhosis (PBC), sponsored by Gilead Sciences. Terminated at 49 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Why this study was terminated
Study stopped early after review of safety and efficacy demonstrated efficacy proof-of-concept and need for dose reduction.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences — 2 open to participants now, 3 under way, 2 of them phase 3. Liver Cirrhosis, Biliary · Gilead Sciences.

Enrollment
9th of 10
41 · median 126
Started
2015
the only one that year
Phase 2
4 of 10
1 open now
Registered
1st of 10
by date

Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, this one is the 9th largest by enrollment, is the only one that started in 2015, is one of 4 in phase 2, and was the 1st registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

2 of the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of seladelpar (MBX-8025) on alkaline phosphatase (AP) levels in participants with primary biliary cirrhosis (PBC).

Read the detailed description

Primary:

To evaluate the effect of MBX-8025 on Alkaline Phosphatase (AP) levels

Secondary:

To evaluate the safety and tolerability of MBX-8025 in subjects with Primary Biliary Cirrhosis (PBC) To evaluate the effects of MBX-8025 on Primary Biliary Cirrhosis (PBC) response criteria To evaluate the effects of MBX-8025 on other markers of liver function, lipids, pruritus and Quality of Life (QoL)

03

Conditions studied

  • Primary Biliary Cirrhosis (PBC)

Keywords

  • PBC
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written (signed and dated) and any authorizations required by local law
  2. 18 to 75 years old (inclusive)
  3. Male or female with a diagnosis of PBC, by at least two of the following criteria:

    • History of AP above (ULN) for at least six months
    • Positive Anti-Mitochondrial Antibodies (AMA) titers (>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies
    • Documented liver result consistent with PBC
  4. On a stable and recommended dose of UDCA for the past twelve months
  5. AP ≥ 1.67 × ULN
  6. For females of , use of at least one barrier and a second effective birth control method during the study and for at least two weeks after the last dose. For male subjects, use of appropriate contraception (e.g., condoms), so their female partners of reproductive potential do not become pregnant during the study and for at least two weeks after the last dose

Exclusion criteria

Exclusion Criteria:

  1. A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer on active treatment)
  2. (AST) or Alanine Aminotransferase (ALT) > 3 ×
  3. Total > 2 × ULN
  4. Auto-immune hepatitis
  5. Primary sclerosing cholangitis
  6. Known history of alpha-1-Antitrypsin deficiency
  7. Known history of chronic viral hepatitis
  8. Creatine kinase above ULN
  9. Serum creatinine above ULN
  10. For females, pregnancy or breast-feeding
  11. Use of colchicine, methotrexate, azathioprine, or systemic in the two months preceding screening
  12. Current use of fibrates, including fenofibrates, or simvastatin
  13. Use of an experimental treatment for PBC
  14. Use of experimental or unapproved
  15. Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Placebo comparator
    Placebo Dose

    Participants received 2 placebo-to-match (PTM) seladelpar capsules, orally, once daily for 12 weeks.

    Drug: Placebo Comparator

  • Experimental
    Seladelpar 50 mg Dose

    Participants received seladelpar 50 mg capsule (1 x 50 mg capsule) and a PTM seladelpar capsule, orally, once daily for 12 weeks.

    Drug: Placebo Comparator · Drug: Experimental: Seladelpar 50 mg

  • Experimental
    Seladelpar 200 mg Dose

    Participants received seladelpar 200 mg capsules (2 x 100 mg capsules), orally, once daily for 12 weeks.

    Drug: Experimental: Seladelpar / MBX-8025 200 mg

Interventions

  • DrugPlacebo Comparator

    Placebo Capsule

    Also known as: Placebo

  • Seladelpar 50 mg capsule

    Also known as: MBX-8025, Livdelzi®

  • DrugExperimental: Seladelpar / MBX-8025 200 mg

    Drug page: Seladelpar

    Seladelpar 100 mg capsules

    Also known as: MBX-8025, Livdelzi®

06

What researchers measure

Primary outcomes

  1. Baseline Alkaline Phosphatase (AP) Levels

    Baseline for AP level was defined as the mean between assessments at Visit 1 (Week -4 to Week 0) and Visit 2 (Week 0).

    Time frame: Baseline

  2. Percent Change From Baseline in Alkaline Phosphatase (AP) Levels

    Percent change in AP serum levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by last observation carried forward (LOCF). Baseline for AP level was defined as the mean between assessments at Visit 1 (Week -4 to Week 0) and Visit 2 (Week 0).

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percentage of Participants With Response as Determined by Composite Endpoint of Alkaline Phosphatase and Total Bilirubin

    Participants were defined as responders for the composite endpoint of AP and total bilirubin if their AP level was \<1.67 × upper limit of normal (ULN) and had decreased at least 15% from their Baseline level and their total bilirubin value was within the normal range \[0.1-1.1 milligrams/deciliter (mg/dL)\].

    Time frame: Week 12

  2. Percent Change From Baseline in Aspartate Aminotransferase (AST)

    Percentage change in AST levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for AST level was defined as the last non-missing assessments prior to or on the date of the first study dose.

    Time frame: Baseline, Week 12

  3. Percent Change From Baseline in Alanine Aminotransferase (ALT)

    Percentage change in ALT levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for ALT level was defined as the last non-missing assessments prior to or on the date of the first study dose.

    Time frame: Baseline, Week 12

  4. Percent Change From Baseline in Gamma-glutamyl Transferase (GGT)

    Percentage change in GGT levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for GGT level was defined as the last non-missing assessments prior to or on the date of the first study dose.

    Time frame: Baseline, Week 12

  5. Percent Change From Baseline in 5'Nucleotidase (5NT)

    Percentage change in 5'Nucleotidase levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for 5NT level was defined as the last non-missing assessments prior to or on the date of the first study dose.

    Time frame: Baseline, Week 12

  6. Percent Change From Baseline in Total Bilirubin

    Percentage change in total bilirubin levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for total bilirubin level was defined as the last non-missing assessments prior to or on the date of the first study dose.

    Time frame: Baseline, Week 12

  7. Percent Change From Baseline in Conjugated Bilirubin

    Percentage change in conjugated bilirubin levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for conjugated bilirubin level was defined as the last non-missing assessments prior to or on the date of the first study dose.

    Time frame: Baseline, Week 12

  8. Percent Change From Baseline in Unconjugated Bilirubin

    Percentage change in unconjugated bilirubin levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for unconjugated bilirubin level was defined as the last non-missing assessments prior to or on the date of the first study dose.

    Time frame: Baseline, Week 12

  9. Percent Change From Baseline in Bone-specific AP Levels

    Percentage change in bone-specific AP levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for bone-specific level was defined as the last non-missing assessments prior to or on the date of the first study dose.

    Time frame: Baseline, Week 12

  10. Percent Change From Baseline in Triglycerides (TG)

    Percentage change in TG levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for TG level was defined as the last non-missing assessments prior to or on the date of the first study dose.

    Time frame: Baseline, Week 12

  11. Percent Change From Baseline in Total Cholesterol (TC)

    Percentage change in TC levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for TC level was defined as the last non-missing assessments prior to or on the date of the first study dose.

    Time frame: Baseline, Week 12

  12. Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)

    Percentage change in HDL-C levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for HDL-C level was defined as the last non-missing assessments prior to or on the date of the first study dose.

    Time frame: Baseline, Week 12

  13. Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)

    Percentage change in LDL-C levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for LDL-C level was defined as the last non-missing assessments prior to or on the date of the first study dose.

    Time frame: Baseline, Week 12

  14. Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Paris I)

    Published criteria for response to treatment in PBC included Paris I criteria. For Paris I, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 3x ULN and AST ≤ 2x ULN and Total Bilirubin ≤ 1 mg/dL. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.

    Time frame: Week 12

  15. Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Paris II)

    Published criteria for response to treatment in PBC included Paris II criteria. For Paris II, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 1.5x ULN and AST ≤ 1.5x ULN and Total Bilirubin ≤ 1 mg/dL. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.

    Time frame: Week 12

  16. Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Toronto I)

    Published criteria for response to treatment in PBC included Toronto I criteria. For Toronto I, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 1.67x ULN. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.

    Time frame: Week 12

  17. Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Toronto II)

    Published criteria for response to treatment in PBC included Toronto II criteria. For Toronto II, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 1.76x ULN. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.

    Time frame: Week 12

  18. United Kingdom-Primary Biliary Cirrhosis/Cholangitis (UK-PBC) Risk Score

    The UK-PBC Risk Score was used to estimate the risk that a PBC participant would develop liver failure that would require liver transplantation within 5, 10 or 15 years from diagnosis. The UK-PBC Risk Score calculation was adapted based on the AP assessment, transaminases (refers to the ALT, where available, otherwise the AST assessment) and total bilirubin assessment respectively at end of treatment divided by its upper limits of the corresponding normal ranges; "albumin" and "platelet" refer to the baseline values of these parameters divided by their corresponding lower limits of normal ranges. Missing assessments at end of treatment was imputed by last observation carried forward (LOCF). The UK-PBC risk scores for 5, 10 and 15 years was calculated for each treatment group

    Time frame: Week 12

  19. Change From Baseline in 5-Dimension (5-D) Itch Scale Score

    The 5-D itch scale was used to for the multidimensional quantification of pruritus over time. It assessed five aspects of itching: degree, duration, direction, disability, and distribution.The 5-D itch Scale is a measure of itching that has been validated in patients with chronic pruritus to detect changes over time. A 5-D itch scale score typically ranges from 5 to 25 with a higher score indicating greater itch severity, where 5 represents no pruritus (itching) and 25 represents the most severe pruritus; Each dimension is scored separately, and the scores are added together to get a total 5-D itch score. Higher scores indicate worsening of itching. The total 5-D itch Scale score change from Baseline was calculated. Baseline for 5-D itch scale was defined as the last non-missing assessments prior to or on the date of the first study dose. Missing assessments at end of treatment was imputed by LOCF.

    Time frame: Baseline, Week 12

  20. Change From Baseline in Pruritus Visual Analog Scale (VAS) Score

    VAS was used to measure pruritis in participants with PBC. Participants placed a mark representing their level of itching since the previous measurement on a 100-mm VAS with 0 indicating no itching and 100 mm indicating the worst possible itching. Higher scores indicated worsening of itching The change from Baseline was presented by treatment group. Baseline for VAS score was defined as the last non-missing assessments prior to or on the date of the first study dose. Missing assessments at end of treatment was imputed by LOCF.

    Time frame: Baseline, Week 12

  21. Change From Baseline in PBC-40 Quality of Life Questionnaire

    The PBC-40 questionnaire was used to evaluate health-related quality of life measures, specifically fatigue. The PBC-40 questionnaire is a disease-specific tool developed to specifically measure the psychometric profile of PBC patients. It consists of 40 items divided into the six domains relevant to PBC including Cognitive, Social, EmotionalFunction, Fatigue, Itch, and Other Symptoms/General Questions. Items are scored from 1 to 5 and individual items scores are summed to give a total domain score. PBC 40 QoL domain score ranges are:Cognitive (6-30), Emotional Function (3-15),Fatigue (11-55), Itch (3-15),Social (10-50),Symptoms (7-35).Higher scores represent high impact and lower scores low impact of PBC on quality of life.The change and percentage change from Baseline for individual domain score at end of treatment were reported. Baseline for PBC-40 questionnaire was the last non-missing assessments prior to or on the date of the first study dose.Missing assessments imputed by LOCF.

    Time frame: Baseline, Week 12

07

Results

Posted Feb 25, 2025
Limitations and caveats
Because the study was discontinued before its completion, the interpretation of the results is limited by the small sample size and some imbalance in baseline characteristics.

Participant flow

Participants were enrolled at study sites in Canada, Germany, the United Kingdom, and the United States.

Participant flow — Overall Study
MilestoneSeladelpar 200 mgSeladelpar 50 mgPlacebo
Started131414
Completed244
Not completed111010
Withdrew: Adverse event300
Withdrew: Randomized but never treated111
Withdrew: Withdrawal of informed consent100
Withdrew: Reason not specified699

Outcome measures

PrimaryBaseline Alkaline Phosphatase (AP) Levels

Baseline for AP level was defined as the mean between assessments at Visit 1 (Week -4 to Week 0) and Visit 2 (Week 0).

Time frame:
Baseline
Reported as:
Mean · units per liter (U/L)
Baseline Alkaline Phosphatase (AP) Levels
units per liter (U/L)Seladelpar 200 mgSeladelpar 50 mgPlacebo
Baseline Alkaline Phosphatase (AP) Levels248.3 ± 88.69311.6 ± 94.83232.8 ± 72.51
PrimaryPercent Change From Baseline in Alkaline Phosphatase (AP) Levels

Percent change in AP serum levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by last observation carried forward (LOCF). Baseline for AP level was defined as the mean between assessments at Visit 1 (Week -4 to Week 0) and Visit 2 (Week 0).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change in AP levels
Percent Change From Baseline in Alkaline Phosphatase (AP) Levels
percent change in AP levelsSeladelpar 200 mgSeladelpar 50 mgPlacebo
Percent Change From Baseline in Alkaline Phosphatase (AP) Levels-62.83 ± 4.312-53.21 ± 3.961-1.84 ± 4.020
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = <0.0001 (Difference in mean,p-value, and CIs estimated by comparing Seladelpar level with placebo by ANCOVA model.Treatment group as factor,baseline AP assessment as covariate,and percent change from baseline as response variable.) · Difference in lsm: -60.99 · 95% CI -72.85 to -49.13
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = <0.0001 (Difference in mean,p-value, and confidence intervals (CIs) estimated by comparing Seladelpar level with placebo by ANCOVA model.Treatment group as factor,baseline AP assessment as covariate,and percent change from baseline as response variable.) · Difference in least squares mean (lsm): -51.37 · 95% CI -63.30 to -39.44
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.1167 (Difference in mean,p-value, and CIs estimated by comparing Seladelpar 200 mg versus 50 mg by ANCOVA model.Treatment group as factor,baseline AP assessment as covariate,and percent change from baseline as response variable.) · Difference in least squares mean (lsm): -9.62 · 95% CI -21.79 to 2.54
SecondaryPercentage of Participants With Response as Determined by Composite Endpoint of Alkaline Phosphatase and Total Bilirubin

Participants were defined as responders for the composite endpoint of AP and total bilirubin if their AP level was \<1.67 × upper limit of normal (ULN) and had decreased at least 15% from their Baseline level and their total bilirubin value was within the normal range \[0.1-1.1 milligrams/deciliter (mg/dL)\].

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Response as Determined by Composite Endpoint of Alkaline Phosphatase and Total Bilirubin
percentage of participantsSeladelpar 200 mgSeladelpar 50 mgPlacebo
Percentage of Participants With Response as Determined by Composite Endpoint of Alkaline Phosphatase and Total Bilirubin10069.28.3
Statistical analysis
  • Seladelpar 200 mg vs Placebo · Fisher Exact · p = <0.0001 (The p-values were calculated from Fisher's exact test comparing each Seladelpar group with Placebo separately.)
  • Seladelpar 50 mg vs Placebo · Fisher Exact · p = 0.0036 (The p-values were calculated from Fisher's exact test comparing each Seladelpar group with Placebo separately.)
  • Seladelpar 200 mg vs Seladelpar 50 mg · Fisher Exact · p = 0.1045 (The p-values were calculated from Fisher's exact test comparing Seladelpar 200mg versus 50 mg.)
SecondaryPercent Change From Baseline in Aspartate Aminotransferase (AST)

Percentage change in AST levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for AST level was defined as the last non-missing assessments prior to or on the date of the first study dose.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change in AST levels
Percent Change From Baseline in Aspartate Aminotransferase (AST)
percent change in AST levelsSeladelpar 200 mgSeladelpar 50 mgPlacebo
Percent Change From Baseline in Aspartate Aminotransferase (AST)232.69 ± 77.409130.81 ± 66.933-2.02 ± 69.364
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.0322 (Difference between means, p-value, and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor, baseline AST assessment as covariate,and percent change from baseline in AST as response variable.) · Difference in lsm: 234.71 · 95% CI 21.28 to 448.14
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.1764 (Difference between means, p-value, and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor, baseline AST assessment as covariate,and percent change from baseline in AST as response variable.) · Difference in lsm: 132.82 · 95% CI -63.00 to 328.65
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.3326 (Difference between means, p-value, and CIs are estimated by comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as factor, baseline AST assessment as covariate, and percent change from baseline in AST as response variable.) · Difference in lsm: 101.88 · 95% CI -109.21 to 312.98
SecondaryPercent Change From Baseline in Alanine Aminotransferase (ALT)

Percentage change in ALT levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for ALT level was defined as the last non-missing assessments prior to or on the date of the first study dose.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change in ALT levels
Percent Change From Baseline in Alanine Aminotransferase (ALT)
percent change in ALT levelsSeladelpar 200 mgSeladelpar 50 mgPlacebo
Percent Change From Baseline in Alanine Aminotransferase (ALT)181.11 ± 77.864111.83 ± 68.061-4.67 ± 69.632
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.0849 (Difference between means,p-value, and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as a factor, baseline ALT assessment as covariate,and percent change from baseline in ALT as response variable.) · Difference in lsm: 185.78 · 95% CI -27.10 to 398.66
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.2409 (Difference between means,p-value,and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as a factor,baseline ALT assessment as covariate, and percent change from baseline in ALT as response variable.) · Difference in lsm: 116.50 · 95% CI -82.22 to 315.23
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.5154 (Difference between means,p-value,and CIs are estimated by comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as a factor,baseline ALT assessment as covariate, and percent change from baseline in ALT as response variable.) · Difference in lsm: 69.28 · 95% CI -145.47 to 284.03
SecondaryPercent Change From Baseline in Gamma-glutamyl Transferase (GGT)

Percentage change in GGT levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for GGT level was defined as the last non-missing assessments prior to or on the date of the first study dose.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change in GGT levels
Percent Change From Baseline in Gamma-glutamyl Transferase (GGT)
percent change in GGT levelsSeladelpar 200 mgSeladelpar 50 mgPlacebo
Percent Change From Baseline in Gamma-glutamyl Transferase (GGT)-47.17 ± 9.084-42.60 ± 7.796-1.83 ± 7.889
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.0007 (Difference between means, p-value,and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as a factor, baseline GGT assessment as covariate,and percent change from baseline in GGT as response variable.) · Difference in lsm: -45.34 · 95% CI -70.04 to -20.64
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.0008 (Difference between means, p-value,and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as a factor, baseline GGT assessment as covariate,and percent change from baseline in GGT as response variable.) · Difference in lsm: -40.78 · 95% CI -63.28 to -18.28
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.7155 (Difference between means, p-value,and CIs are estimated by comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as a factor, baseline GGT assessment as covariate,and percent change from baseline in GGT as response variable.) · Difference in lsm: -4.56 · 95% CI -29.85 to 20.73
SecondaryPercent Change From Baseline in 5'Nucleotidase (5NT)

Percentage change in 5'Nucleotidase levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for 5NT level was defined as the last non-missing assessments prior to or on the date of the first study dose.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change in 5'Nucleotidase levels
Percent Change From Baseline in 5'Nucleotidase (5NT)
percent change in 5'Nucleotidase levelsSeladelpar 200 mgSeladelpar 50 mgPlacebo
Percent Change From Baseline in 5'Nucleotidase (5NT)-34.35 ± 8.446-24.92 ± 7.148-0.08 ± 7.305
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.0050 (Difference between means,p-value, and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as a factor, baseline 5NT assessment as covariate,and percent change from baseline in 5NT as response variable.) · Difference in lsm: -34.27 · 95% CI -57.40 to -11.14
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.0199 (Difference between means,p-value, and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as a factor, baseline 5NT assessment as covariate,and percent change from baseline in 5NT as response variable.) · Difference in lsm: -24.84 · 95% CI -45.47 to -4.21
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.4161 (Difference between means,p-value, and CIs are estimated by comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as a factor, baseline 5NT assessment as covariate,and percent change from baseline in 5NT as response variable.) · Difference in lsm: -9.43 · 95% CI -32.77 to 13.90
SecondaryPercent Change From Baseline in Total Bilirubin

Percentage change in total bilirubin levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for total bilirubin level was defined as the last non-missing assessments prior to or on the date of the first study dose.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change in total bilirubin levels
Percent Change From Baseline in Total Bilirubin
percent change in total bilirubin levelsSeladelpar 200 mgSeladelpar 50 mgPlacebo
Percent Change From Baseline in Total Bilirubin1.40 ± 6.384-16.79 ± 5.586-4.79 ± 5.793
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.4780 (Difference between means,p-value, and CIs estimated by comparing each Seladelpar level with placebo by ANCOVA model.Treatment group as factor, baseline assessment as covariate, and percent change from baseline in total bilirubin as response variable.) · Difference in lsm: 6.20 · 95% CI -11.40 to 23.79
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.1459 (Difference between means,p-value, and CIs estimated by comparing each Seladelpar level with placebo by ANCOVA model.Treatment group as factor, baseline assessment as covariate, and percent change from baseline in total bilirubin as response variable.) · Difference in lsm: -12.00 · 95% CI -28.40 to 4.41
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.0407 (Difference between means,p-value, and CIs estimated by comparing Seladelpar 200 mg versus 50 mg by ANCOVA model.Treatment group as factor, baseline assessment as covariate, and percent change from baseline in total bilirubin as response variable.) · Difference in lsm: 18.19 · 95% CI 0.82 to 35.57
SecondaryPercent Change From Baseline in Conjugated Bilirubin

Percentage change in conjugated bilirubin levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for conjugated bilirubin level was defined as the last non-missing assessments prior to or on the date of the first study dose.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change in conjugated bilirubin
Percent Change From Baseline in Conjugated Bilirubin
percent change in conjugated bilirubinSeladelpar 200 mgSeladelpar 50 mgPlacebo
Percent Change From Baseline in Conjugated Bilirubin42.30 ± 10.2132.00 ± 8.93210.84 ± 9.296
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.0300 (Difference between means,p-value,and CIs are estimated by each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline assessment as covariate,and percent change from baseline in conjugated bilirubin as response variable.) · Difference in lsm: 31.47 · 95% CI 3.26 to 59.67
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.4979 (Difference between means,p-value,and CIs are estimated by each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline assessment as covariate,and percent change from baseline in conjugated bilirubin as response variable.) · Difference in lsm: -8.84 · 95% CI -35.11 to 17.44
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.0058 (Difference between means,p-value,and CIs are estimated for Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as factor,baseline assessment as covariate,and percent change from baseline in conjugated bilirubin as response variable.) · Difference in lsm: 40.30 · 95% CI 12.58 to 68.02
SecondaryPercent Change From Baseline in Unconjugated Bilirubin

Percentage change in unconjugated bilirubin levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for unconjugated bilirubin level was defined as the last non-missing assessments prior to or on the date of the first study dose.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change in unconjugated bilirubin
Percent Change From Baseline in Unconjugated Bilirubin
percent change in unconjugated bilirubinSeladelpar 200 mgSeladelpar 50 mgPlacebo
Percent Change From Baseline in Unconjugated Bilirubin-11.86 ± 6.197-23.04 ± 5.431-8.89 ± 5.620
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.7244 (Difference between means,p-value, and CIs are estimated by comparing Seladelpar level with placebo using ANCOVA model.Treatment group as a factor,baseline assessment as covariate, and percent change from baseline as the response variable.) · Difference in lsm: -2.97 · 95% CI -20.03 to 14.08
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.0800 (Difference between means,p-value, and CIs are estimated by comparing Seladelpar level with placebo using ANCOVA model.Treatment group as a factor,baseline assessment as covariate, and percent change from baseline as the response variable.) · Difference in lsm: -14.15 · 95% CI -30.10 to 1.80
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.1874 (Difference between means,p-value, and CIs are estimated by comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as a factor,baseline assessment as covariate, and percent change from baseline as the response variable.) · Difference in lsm: 11.18 · 95% CI -5.73 to 28.08
SecondaryPercent Change From Baseline in Bone-specific AP Levels

Percentage change in bone-specific AP levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for bone-specific level was defined as the last non-missing assessments prior to or on the date of the first study dose.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change in bone-specific AP level
Percent Change From Baseline in Bone-specific AP Levels
percent change in bone-specific AP levelSeladelpar 200 mgSeladelpar 50 mgPlacebo
Percent Change From Baseline in Bone-specific AP Levels-50.39 ± 4.837-39.09 ± 4.355-4.43 ± 4.544
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = <0.0001 (Difference between means,p-value,and CIs are estimated comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline bone-specific AP assessment as covariate,and percent change from baseline as response variable.) · Difference in lsm: -45.96 · 95% CI -59.50 to -32.42
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = <0.0001 (Difference between means,p-value,and CIs are estimated comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline bone-specific AP assessment as covariate,and percent change from baseline as response variable.) · Difference in lsm: -34.66 · 95% CI -47.83 to -21.48
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.0924 (Difference between means,p-value,and CIs are estimated comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as factor,baseline bone-specific AP assessment as covariate,and percent change from baseline as response variable.) · Difference in lsm: -11.30 · 95% CI -24.58 to 1.97
SecondaryPercent Change From Baseline in Triglycerides (TG)

Percentage change in TG levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for TG level was defined as the last non-missing assessments prior to or on the date of the first study dose.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change in TG levels
Percent Change From Baseline in Triglycerides (TG)
percent change in TG levelsSeladelpar 200 mgSeladelpar 50 mgPlacebo
Percent Change From Baseline in Triglycerides (TG)-7.11 ± 9.415-30.27 ± 8.2437.04 ± 8.617
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.2777 (Difference between means,p-value, and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor, baseline TG assessment as a covariate, and percent change from baseline in TG as response variable.) · Difference in lsm: -14.15 · 95% CI -40.27 to 11.97
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.0039 (Difference between means,p-value, and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor, baseline TG assessment as a covariate, and percent change from baseline in TG as response variable.) · Difference in lsm: -37.31 · 95% CI -61.67 to -12.95
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.0734 (Difference between means,p-value, and CIs are estimated by comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as factor, baseline TG assessment as a covariate, and percent change from baseline in TG as response variable.) · Difference in lsm: 23.16 · 95% CI -2.33 to 48.65
SecondaryPercent Change From Baseline in Total Cholesterol (TC)

Percentage change in TC levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for TC level was defined as the last non-missing assessments prior to or on the date of the first study dose.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change in TC levels
Percent Change From Baseline in Total Cholesterol (TC)
percent change in TC levelsSeladelpar 200 mgSeladelpar 50 mgPlacebo
Percent Change From Baseline in Total Cholesterol (TC)-16.43 ± 3.250-8.44 ± 2.774-0.32 ± 2.905
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.0010 (Difference between means,p-value,and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor, baseline TC assessment as covariate,and percent change from baseline in TC as the response variable.) · Difference in lsm: -16.12 · 95% CI -25.16 to -7.07
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.0504 (Difference between means,p-value,and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor, baseline TC assessment as covariate,and percent change from baseline in TC as the response variable.) · Difference in lsm: -8.13 · 95% CI -16.27 to 0.02
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.0738 (Difference between means,p-value,and CIs are estimated by comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as factor, baseline TC assessment as covariate,and percent change from baseline in TC as the response variable.) · Difference in lsm: -7.99 · 95% CI -16.80 to 0.81
SecondaryPercent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)

Percentage change in HDL-C levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for HDL-C level was defined as the last non-missing assessments prior to or on the date of the first study dose.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change in HDL-C levels
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)
percent change in HDL-C levelsSeladelpar 200 mgSeladelpar 50 mgPlacebo
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)-13.06 ± 4.3263.44 ± 3.7474.33 ± 3.884
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.0057 (Difference between means,p-value,and CIs estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline HDL-C assessment as covariate,and percent change from baseline in HDL-C as response variable.) · Difference in lsm: -17.39 · 95% CI -29.32 to -5.46
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.8703 (Difference between means,p-value,and CIs estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline HDL-C assessment as covariate,and percent change from baseline in HDL-C as response variable.) · Difference in lsm: -0.89 · 95% CI -11.85 to 10.08
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.0076 (Difference between means,p-value,and CIs estimated by comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as factor,baseline HDL-C assessment as covariate,and percent change from baseline in HDL-C as response variable.) · Difference in lsm: -16.51 · 95% CI -28.30 to -4.71
SecondaryPercent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)

Percentage change in LDL-C levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for LDL-C level was defined as the last non-missing assessments prior to or on the date of the first study dose.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change in LDL-C levels
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)
percent change in LDL-C levelsSeladelpar 200 mgSeladelpar 50 mgPlacebo
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)-17.63 ± 4.372-12.83 ± 3.763-2.78 ± 3.958
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.0186 (Difference between means,p-value, and CIs estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline LDL-C assessment as covariate,and percent change from baseline in LDL-C as response variable.) · Difference in lsm: -14.85 · 95% CI -27.05 to -2.66
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.0745 (Difference between means,p-value, and CIs estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline LDL-C assessment as covariate,and percent change from baseline in LDL-C as response variable.) · Difference in lsm: -10.06 · 95% CI -21.17 to 1.06
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.4131 (Difference between means,p-value, and CIs estimated by comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as factor,baseline LDL-C assessment as covariate,and percent change from baseline in LDL-C as response variable.) · Difference in lsm: -4.80 · 95% CI -16.60 to 7.00
SecondaryNumber of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Paris I)

Published criteria for response to treatment in PBC included Paris I criteria. For Paris I, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 3x ULN and AST ≤ 2x ULN and Total Bilirubin ≤ 1 mg/dL. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Paris I)
ParticipantsSeladelpar 200 mgSeladelpar 50 mgPlacebo
Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Paris I)222
Statistical analysis
  • Seladelpar 50 mg vs Placebo · Fisher Exact · p = 0.4667 (Fisher's exact test between each Seladelpar level compared with placebo was used to obtain the p-value.)
  • Seladelpar 200 mg vs Seladelpar 50 mg · Fisher Exact · p = 0.4667 (Fisher's exact test between Seladelpar 200 mg versus 50 mg was used to obtain the p-value.)
SecondaryNumber of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Paris II)

Published criteria for response to treatment in PBC included Paris II criteria. For Paris II, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 1.5x ULN and AST ≤ 1.5x ULN and Total Bilirubin ≤ 1 mg/dL. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Paris II)
ParticipantsSeladelpar 200 mgSeladelpar 50 mgPlacebo
Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Paris II)589
Statistical analysis
  • Seladelpar 200 mg vs Placebo · Fisher Exact · p = 0.0824 (Fisher's exact test between each Seladelpar level compared with placebo was used to obtain the p-value.)
  • Seladelpar 50 mg vs Placebo · Fisher Exact · p = 0.0537 (Fisher's exact test between each Seladelpar level compared with placebo was used to obtain the p-value.)
  • Seladelpar 200 mg vs Seladelpar 50 mg · Fisher Exact · p = 1.0000 (Fisher's exact test between Seladelpar 200 mg versus 50 mg was used to obtain the p-value.)
SecondaryNumber of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Toronto I)

Published criteria for response to treatment in PBC included Toronto I criteria. For Toronto I, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 1.67x ULN. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Toronto I)
ParticipantsSeladelpar 200 mgSeladelpar 50 mgPlacebo
Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Toronto I)037
Statistical analysis
  • Seladelpar 200 mg vs Placebo · Fisher Exact · p = 0.0101 (Fisher's exact test between each Seladelpar level compared with placebo was used to obtain the p-value.)
  • Seladelpar 50 mg vs Placebo · Fisher Exact · p = 0.0198 (Fisher's exact test between each Seladelpar level compared with placebo was used to obtain the p-value.)
  • Seladelpar 200 mg vs Seladelpar 50 mg · Fisher Exact · p = 0.5165 (Fisher's exact test between Seladelpar 200 mg versus 50 mg was used to obtain the p-value.)
SecondaryNumber of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Toronto II)

Published criteria for response to treatment in PBC included Toronto II criteria. For Toronto II, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 1.76x ULN. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Toronto II)
ParticipantsSeladelpar 200 mgSeladelpar 50 mgPlacebo
Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Toronto II)027
Statistical analysis
  • Seladelpar 200 mg vs Placebo · Fisher Exact · p = 0.0101 (Fisher's exact test between each Seladelpar level compared with placebo was used to obtain the p-value.)
  • Seladelpar 50 mg vs Placebo · Fisher Exact · p = 0.0055 (Fisher's exact test between each Seladelpar level compared with placebo was used to obtain the p-value.)
  • Seladelpar 200 mg vs Seladelpar 50 mg · Fisher Exact · p = 1.0000 (Fisher's exact test between Seladelpar 200 mg versus 50 mg was used to obtain the p-value.)
SecondaryUnited Kingdom-Primary Biliary Cirrhosis/Cholangitis (UK-PBC) Risk Score

The UK-PBC Risk Score was used to estimate the risk that a PBC participant would develop liver failure that would require liver transplantation within 5, 10 or 15 years from diagnosis. The UK-PBC Risk Score calculation was adapted based on the AP assessment, transaminases (refers to the ALT, where available, otherwise the AST assessment) and total bilirubin assessment respectively at end of treatment divided by its upper limits of the corresponding normal ranges; "albumin" and "platelet" refer to the baseline values of these parameters divided by their corresponding lower limits of normal ranges. Missing assessments at end of treatment was imputed by last observation carried forward (LOCF). The UK-PBC risk scores for 5, 10 and 15 years was calculated for each treatment group

Time frame:
Week 12
Reported as:
Mean · percentage risk
United Kingdom-Primary Biliary Cirrhosis/Cholangitis (UK-PBC) Risk Score
percentage riskSeladelpar 200 mgSeladelpar 50 mgPlacebo
UK-PBC Risk Score by 5 years1.3642 ± 0.954521.8530 ± 2.323013.1102 ± 5.1892
UK-PBC Risk Score by 10 years3.9796 ± 2.740815.2712 ± 6.318428.3004 ± 12.51699
UK-PBC Risk Score by 15 years6.4392 ± 4.367378.3379 ± 9.5718412.4804 ± 17.05244
SecondaryChange From Baseline in 5-Dimension (5-D) Itch Scale Score

The 5-D itch scale was used to for the multidimensional quantification of pruritus over time. It assessed five aspects of itching: degree, duration, direction, disability, and distribution.The 5-D itch Scale is a measure of itching that has been validated in patients with chronic pruritus to detect changes over time. A 5-D itch scale score typically ranges from 5 to 25 with a higher score indicating greater itch severity, where 5 represents no pruritus (itching) and 25 represents the most severe pruritus; Each dimension is scored separately, and the scores are added together to get a total 5-D itch score. Higher scores indicate worsening of itching. The total 5-D itch Scale score change from Baseline was calculated. Baseline for 5-D itch scale was defined as the last non-missing assessments prior to or on the date of the first study dose. Missing assessments at end of treatment was imputed by LOCF.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in 5-Dimension (5-D) Itch Scale Score
score on a scaleSeladelpar 200 mgSeladelpar 50 mgPlacebo
Change From Baseline in 5-Dimension (5-D) Itch Scale Score-0.9 ± 1.310.5 ± 1.150.2 ± 1.25
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.5379 (Difference between means,p-value, and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor, baseline score as covariate, and change from baseline score as the response variable.) · Difference in lsm: -1.1 · 95% CI -4.8 to 2.6
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.8949 (Difference between means,p-value, and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor, baseline score as covariate, and change from baseline score as the response variable.) · Difference in lsm: 0.2 · 95% CI -3.3 to 3.7
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.4431 (Difference between means,p-value, and CIs are estimated by comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as factor, baseline score as covariate, and change from baseline score as the response variable.) · Difference in lsm: -1.4 · 95% CI -4.9 to 2.2
SecondaryChange From Baseline in Pruritus Visual Analog Scale (VAS) Score

VAS was used to measure pruritis in participants with PBC. Participants placed a mark representing their level of itching since the previous measurement on a 100-mm VAS with 0 indicating no itching and 100 mm indicating the worst possible itching. Higher scores indicated worsening of itching The change from Baseline was presented by treatment group. Baseline for VAS score was defined as the last non-missing assessments prior to or on the date of the first study dose. Missing assessments at end of treatment was imputed by LOCF.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Pruritus Visual Analog Scale (VAS) Score
score on a scaleSeladelpar 200 mgSeladelpar 50 mgPlacebo
Change From Baseline in Pruritus Visual Analog Scale (VAS) Score0.9 ± 7.54-0.7 ± 6.358.3 ± 6.42
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.4674 (Difference between means,p-value, and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model. Treatment group as factor, baseline score as a covariate, and change from baseline score as the response variable.) · Difference in lsm: -7.4 · 95% CI -28.0 to 13.2
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.3236 (Difference between means,p-value, and CIs are estimated by comparing each Seladelpar level with placebo using ANCOVA model. Treatment group as factor, baseline score as a covariate, and change from baseline score as the response variable.) · Difference in lsm: -9.0 · 95% CI -27.4 to 9.4
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.8723 (Difference between means,p-value, and CIs are estimated by comparing Seladelpar 200 mg versus 50 mg using ANCOVA model. Treatment group as factor, baseline score as a covariate, and change from baseline score as the response variable.) · Difference in lsm: 1.6 · 95% CI -18.7 to 21.9
SecondaryChange From Baseline in PBC-40 Quality of Life Questionnaire

The PBC-40 questionnaire was used to evaluate health-related quality of life measures, specifically fatigue. The PBC-40 questionnaire is a disease-specific tool developed to specifically measure the psychometric profile of PBC patients. It consists of 40 items divided into the six domains relevant to PBC including Cognitive, Social, EmotionalFunction, Fatigue, Itch, and Other Symptoms/General Questions. Items are scored from 1 to 5 and individual items scores are summed to give a total domain score. PBC 40 QoL domain score ranges are:Cognitive (6-30), Emotional Function (3-15),Fatigue (11-55), Itch (3-15),Social (10-50),Symptoms (7-35).Higher scores represent high impact and lower scores low impact of PBC on quality of life.The change and percentage change from Baseline for individual domain score at end of treatment were reported. Baseline for PBC-40 questionnaire was the last non-missing assessments prior to or on the date of the first study dose.Missing assessments imputed by LOCF.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in PBC-40 Quality of Life Questionnaire
score on a scaleSeladelpar 200 mgSeladelpar 50 mgPlacebo
Cognitive Domain Score2.6 ± 0.960.9 ± 0.76-0.8 ± 0.80
Social Domain Score3.2 ± 1.320.3 ± 1.06-0.5 ± 1.09
Emotional Function Domain Score0.4 ± 0.730.4 ± 0.580.0 ± 0.62
Fatigue Domain Score-0.3 ± 1.502.3 ± 1.20-1.9 ± 1.26
Itch Domain Score-0.6 ± 0.810.3 ± 0.65-0.4 ± 0.67
Symptoms Domain Score1.1 ± 0.760.9 ± 0.62-1.5 ± 0.64
Statistical analysis
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.0115 (Difference between means,p-value,and CIs are estimated comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: 3.4 · 95% CI 0.8 to 6.0
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.1256 (Difference between means,p-value,and CIs are estimated comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: 1.8 · 95% CI -0.5 to 4.0
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.1842 (Difference between means,p-value,and CIs are estimated comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: 1.7 · 95% CI -0.9 to 4.2
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.0420 (Difference between means,p-value,and CIs are estimated comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: 3.7 · 95% CI 0.1 to 7.2
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.6384 (Difference between means,p-value,and CIs are estimated comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: 0.7 · 95% CI -2.4 to 3.9
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.1035 (Difference between means,p-value,and CIs are estimated comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: 2.9 · 95% CI -0.6 to 6.5
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.6967 (Difference between means,p-value,and CIs are estimated comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: 0.4 · 95% CI -1.6 to 2.4
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.6164 (Difference between means,p-value,and CIs are estimated comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: 0.4 · 95% CI -1.3 to 2.2
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.9548 · Difference in lsm: -0.1 · 95% CI -2.0 to 1.9
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.8286 (Difference between means,p-value,and CIs are estimated comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: -0.2 · 95% CI -2.4 to 1.9
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.0226 (Difference between means,p-value,and CIs are estimated comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: 4.2 · 95% CI 0.6 to 7.8
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.1861 (Difference between means,p-value,and CIs are estimated comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: -2.6 · 95% CI -6.6 to 1.4
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.4159 (Difference between means,p-value,and CIs are estimated comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: 1.6 · 95% CI -2.4 to 5.7
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.4848 (Difference between means,p-value,and CIs are estimated comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: 0.7 · 95% CI -1.3 to 2.6
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.4048 (Difference between means,p-value,and CIs are estimated comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: -0.9 · 95% CI -3.1 to 1.3
  • Seladelpar 200 mg vs Placebo · ANCOVA · p = 0.0141 (Difference between means,p-value,and CIs are estimated comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: 2.6 · 95% CI 0.6 to 4.7
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.0138 (Difference between means,p-value,and CIs are estimated comparing each Seladelpar level with placebo using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: 2.4 · 95% CI 0.5 to 4.2
  • Seladelpar 200 mg vs Seladelpar 50 mg · ANCOVA · p = 0.7911 (Difference between means,p-value,and CIs are estimated comparing Seladelpar 200 mg versus 50 mg using ANCOVA model.Treatment group as factor,baseline PBC 40 QoL domain score as covariate, change from baseline in domain score as response variable.) · Difference in lsm: 0.3 · 95% CI -1.8 to 2.3

Adverse events

Collected over All-cause mortality: Up to 16.4 weeks; Adverse events: Up to 14.7 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Seladelpar 200 mg0/13 (0%)0/12 (0%)10/12 (83.3%)
Seladelpar 50 mg0/14 (0%)0/13 (0%)11/13 (84.6%)
Placebo0/14 (0%)0/13 (0%)10/13 (76.9%)
Most frequent other events
Showing 10 of 55
Most frequent other events
EventSeladelpar 200 mgSeladelpar 50 mgPlacebo
PruritusSkin and subcutaneous tissue disorders1/124/131/13
Muscle spasmsMusculoskeletal and connective tissue disorders3/120/130/13
NauseaGastrointestinal disorders1/123/131/13
Alanine aminotransferase increasedInvestigations2/120/130/13
Aspartate aminotransferase increasedInvestigations2/120/130/13
MyalgiaMusculoskeletal and connective tissue disorders2/120/131/13
DiarrhoeaGastrointestinal disorders1/121/132/13
DyspepsiaGastrointestinal disorders1/122/130/13
DizzinessNervous system disorders0/122/131/13
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/122/130/13

Baseline characteristics

The Safety Population was defined as any randomized participant who received at least 1 dose of medication.

Age, Categorical
Age, Categorical(Participants)Seladelpar 200 mgSeladelpar 50 mgPlaceboTotal
<=18 years0000
Between 18 and 65 years9121233
>=65 years3115
Age, Continuous
Age, Continuous(years)Seladelpar 200 mgSeladelpar 50 mgPlaceboTotal
Mean57 ± 11.454 ± 7.455 ± 10.155 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Seladelpar 200 mgSeladelpar 50 mgPlaceboTotal
Female12121236
Male0112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Seladelpar 200 mgSeladelpar 50 mgPlaceboTotal
Hispanic or Latino0101
Not Hispanic or Latino12121337
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Seladelpar 200 mgSeladelpar 50 mgPlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American2002
White10121335
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Seladelpar 200 mgSeladelpar 50 mgPlaceboTotal
United States65617
United Kingdom2439
Germany3238
Canada1214
08

Study locations

49 sites
  • Mayo Clinic of Arizona
    Phoenix, Arizona 85054, United States
  • University of California, Davis Medical Center
    Sacramento, California 95817, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • University of Miami, Center for Liver Diseases
    Miami, Florida 33136, United States
  • Norman Gitlin, MD
    Atlanta, Georgia 30308, United States
  • Digestive Helathcare of Georgia
    Atlanta, Georgia 30309, United States
  • Indiana University Hospital - Clinical Research Center
    Indianapolis, Indiana 46202, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Gastroenterology Associates of Western Michigan, PLC, d.b.a. West Michigan Clinical Research
    Wyoming, Michigan 49519, United States
  • Kansas City Gastroenterology and Hepatology
    Kansas City, Missouri 64131, United States
  • St. Louis University School of Medicine
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center / The Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • North Shore-Long Island Jewish Health System / Division of Gastroenterology
    Manhasset, New York 11030, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai - The Mount Sinai Medical Center
    New York, New York 10029, United States
  • Consultants for Clinical Research
    Cincinnati, Ohio 45249, United States
  • CHI St. Luke's Health Baylor College of Medicine Medical Center - Advanced Liver Therapies
    Houston, Texas 77030, United States
  • Pinnacle Clinical Research
    Live Oak, Texas 78233, United States
  • American Research Corporation at Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Bon Secours St. Mary's Hospital of Richmond
    Newport News, Virginia 23602, United States
  • Digestive and Liver Disease Specialists
    Norfolk, Virginia 23502, United States
  • University of Calgary Liver Unit (Heritage Medical Research Clinic)
    Calgary, Alberta T2N 4Z6, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Charite Universitatsmedizin Berlin - Campus Mitte
    Berlin, 10117, Germany
  • Leber- und Studienzentrum am Checkpoint
    Berlin, 10969, Germany
  • Universitatsklinikum Bonn
    Bonn, 53127, Germany
  • Universitatsklinikum Carl Gustav Carus an der TU Dresden
    Dresden, 01307, Germany
  • University Hospital Erlangen
    Erlangen, 91054, Germany
  • Universitatsklinikum Essen, Zentrum fur Innere Medizin
    Essen, 45157, Germany
  • Ifi-Studien und Projekte GmbH, A.d. Asklepios Klinik St. Georg
    Hamburg, 20099, Germany
  • Universitatsklinikum Hamburg-Eppendorf MARTINISTRASSE 52
    Hamburg, 20246, Germany
  • Med. Hochschule Hannover, Klinik fur Gastroenterologie
    Hannover, 30625, Germany
  • Medizinische Universitatsklinik
    Heidelberg, 69120, Germany
  • Gastroenterologische Gemeinschaftspraxis Herne
    Herne, 44623, Germany
  • UKSH, Campus Kiel, Klinik fur Allgemeine Innere Medizin 1
    Kiel, 24105, Germany
  • UKSH, Campus Kiel
    Kiel, 24105, Germany
  • Universitatsklinikum Leipzig AOR
    Leipzig, 04103, Germany
  • Universitatsmedizin der Johannes Gutenberg - Universitat Mainz
    Mainz, 55131, Germany
  • Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza w Bydgoszczy
    Bydgoszcz, Kujawsko-pomorskie 85-030, Poland
  • SPZOZ Szpital Uniwersytecki w Krakowie
    Krakow, Malopolski 31-531, Poland
  • Centrum Onkologii-Instytut Im. Marii Sklodowskiej-Curie
    Warszawa, Mazowieckie 02-781, Poland
  • SP CSK im. Prof. K. Gibinskiego SUM w Katowicach
    Katowice, Slaskie 40-752, Poland
  • ID Clinic Arkadiusz Pisula
    Myslowice, Slaskie 41-400, Poland
  • Derriford Hospital
    Plymouth, England PL6 8DH, United Kingdom
  • University Hospital Birmingham NHS Foundation Trust
    Birmingham, B15 2GW, United Kingdom
  • Addenbrooke Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • Hull and East Yorkshire NHS Trust
    Hull, HU3 2jZ, United Kingdom
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Newcastle upon Tyne, NE1 4LP, United Kingdom
  • Nottingham University Hospitals NHS Trust
    Nottingham, NG7 2UH, United Kingdom
09

References and documents

Publications

  • Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC, Odin JA, Sheridan D, Worns MA, Clark V, Corless L, Hartmann H, Jonas ME, Kremer AE, Mells GF, Buggisch P, Freilich BL, Levy C, Vierling JM, Bernstein DE, Hartleb M, Janczewska E, Rochling F, Shah H, Shiffman ML, Smith JH, Choi YJ, Steinberg A, Varga M, Chera H, Martin R, McWherter CA, Hirschfield GM. Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017 Oct;2(10):716-726. doi: 10.1016/S2468-1253(17)30246-7. Epub 2017 Aug 14. PubMed 28818518 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Jul 2016, 7 months.

Results were first posted in Feb 2025, 8 years 7 months after primary completion. A results delay was requested in Jan 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2015
First posted
Nov 20, 2015
StartActual
Nov 4, 2015
Primary completionActual
Jul 1, 2016
CompletionActual
Jul 1, 2016
Results delay requested
Jan 23, 2018
Results first posted
Feb 25, 2025
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02609048
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 20, 2015
Start date
Nov 4, 2015
Primary completion
Jul 1, 2016
Completion
Jul 1, 2016
Results posted
Feb 25, 2025
Last update
Feb 25, 2025

Study contacts

Pol F Boudes, M.D.
study chair · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seladelpar

Start the discussion